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developed for valuation. TTO interviews conducted with 400 respondents who were 
on average 36 (SD 13.5) yrs old; 39.2% male, 60.8% female; 46.4% White British; 
and 19% with COPD experience (self or others). Analyses are currently underway to 
ﬁt and validate a model using the above criteria. CONCLUSIONS: The EXACT-U is 
a condition-speciﬁc preference-based measure for use in clinical trials to evaluate 
change in utility of a COPD exacerbation patient from baseline through to 
resolution.
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OBJECTIVES: To ﬁnalise and establish the scoring algorithm of the 12-item “COPD           
and activities of daily living (ADL)” questionnaire, a tool speciﬁcally developed to 
help in the detection of handicap in COPD patients and determine the handicap level, 
thus optimising COPD management in the primary care setting. METHODS: The 
“COPD and ADL” questionnaire was developed and tested with patients and clini-
cians. It was included for ﬁnalisation and validation in a multi-centre, cross-sectional, 
observational study involving 100 French lung specialists. Patients with COPD stage 
II to IV according to the GOLD classiﬁcation were included. Finalisation of the ques-
tionnaire included: assessment of the quality of completion, veriﬁcation of the unidi-
mensionnality hypothesis using principal component analysis (PCA) and Rasch 
modelling (Partial Credit Model). RESULTS: Sixty lung specialists each included at      
least one patient. Two hundred and eighty two COPD patients were included, of 
whom 272 (96%) returned the “COPD and ADL” questionnaire. The quality of 
completion was very good (91% of questionnaires with no missing data), conﬁrming 
the good acceptability of the items. In the PCA, the ﬁrst factor explained 58% of the 
total variance, conﬁrming the a priori unidimensionnality hypothesis. The items 
“Impact of COPD on sexual life” and “Overall perception of handicap due to COPD” 
were considered for deletion from the score because they had high residual values in 
the Rasch analysis. After reduction to a 10-item score, the ﬁt of the Rasch model was 
acceptable (C2  27.452; p  0.599). CONCLUSIONS: The “COPD and ADL” ques-    
tionnaire is a short instrument assessing the handicap level among COPD patients, 
speciﬁcally designed as a clinical tool to contribute to patient management. The next 
step will be the validation of this instrument, including the assessment of its relation-
ships with other measures of health impairment in COPD patients.
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OBJECTIVES: The Global Initiative for Asthma (GINA) 2006 guidelines were revised 
in order to provide a new classiﬁcation for asthma based on disease control and to 
include new treatment strategies. The aim of the current study was to describe the 
opinion of patients, treated according to GINA 2006 guidelines, regarding their 
asthma control, treatment satisfaction and quality of life (QoL). METHODS: EPAG-
GELIA was a descriptive, cross-sectional Greek study. The study population consisted 
of primary care patients with moderate/severe persistent asthma for q6 months, treated 
according to new strategies, as deﬁned by GINA 2006, for q3 months. Data were 
collected during a single visit via a structured questionnaire. Moreover, participating 
patients completed 3 PROs. SATQ (treatment satisfaction), ACQ-5 (asthma control), 
and MiniAQLQ (QoL). RESULTS: 801 patients (M/F/Missing: 353/443/5, age 49.3 
o 15.5, 65.7% smokers) were enrolled from 104 ofﬁce-based physicians. 40.2% of 
patients reported being “very highly” satisﬁed, 31.9% “highly” satisﬁed, 15.9% 
“adequately” satisﬁed and 12% “moderately” to “not satisﬁed” with their treatment. 
Mean SATQ score was 5.4 o 0.9. 52.6% of patients reported an ACQ-5 a1.0 and 
64% a score of 1.5. Mean ACQ-5 score was 1.3 o 1.1, whereas mean MiniAQLQ 
score was 5.3 o 1.1. Good compliance (no treatment interruption within the previous 
6 months) was shown in 46.1% of patients. ACQ-5, SATQ and MiniAQLQ scores 
in patients with no treatment interruption as compared with those in patients with 
any treatment interruption were 1.2 o 1.2, 5.4 o 0.2, 5.5 o 0.9 vs 1.5 o 1.1, 5.2 o 1.0, 
5.3 o 0.9, respectively. CONCLUSIONS: Primary care asthma patients treated accord-
ing to the 2006 GINA guidelines in Greece, showed a relatively satisfactory asthma 
control and presented with good QoL and treatment satisfaction. However, there is 
room for improvement regarding disease control and treatment compliance. Com-
pliant patients demonstrated relatively better asthma control, QoL and treatment 
satisfaction.
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OBJECTIVES: To assess the health-related quality of life (HRQL) impacts of Xolair® 
(omalizumab), in routine Belgian clinical practice in patients with severe allergic 
asthma naïve to omalizumab. METHODS: A prospective open-label, single arm, 
observational, multicenter study with one year follow-up was conducted. Amongst 
other study outcomes (e.g. treatment effectiveness, exacerbation rate, drug consump-
tion, medical resources used, safety, . . .), HRQL was gauged using validated generic 
and disease speciﬁc instruments, i.e. the European Quality of Life Questionnaire 5 
Dimensions (EQ-5D) and the Asthma Quality of life Questionnaire (AQLQ), respec-
tively. The EQ-5D was administered at baseline and after 1 year, the AQLQ was 
administered at baseline, after 16 weeks of treatment and after one year to mimic 
what is legally required by Belgian authorities. For the EQ-5D, the Flemish value set 
was used to calculate utility scores. Minimally important differences for the EQ-5D 
and AQLQ were previously reported as 0.074–0.120 (depending on the disease con-
sidered) and 0.5, respectively. RESULTS: For this study, 160 patients were enrolled 
from 35 study centers geographically spread over Belgium. A marked improvement in 
EQ-5D was observed following treatment with omalizumab, at one year, a mean 
increase from baseline of 15.4 units for the visual analog scale and 0.13 for the utility 
score (n  71) were reported. These results were corroborated by the AQLQ results 
which showed an improvement from baseline in the total score of 1.37 points at 16 
weeks (n  142) and 1.80 points at one year (n  100). Improvements observed for 
the 4 AQLQ subscales were also consistent. CONCLUSIONS: This observational 
study showed signiﬁcant HRQL improvements, both in the EQ-5D and AQLQ, with 
the use of omalizumab in routine practice amongst patients with severe allergic 
asthma.
PRS37
IMPROVEMENTS IN QUALITY OF LIFE FOR PATIENTS UNDERGOING 
COPD REHABILITATION AT MUNICIPALITY HEALTH CARE  
CENTRES IN DENMARK
Dollerup J1, Poulsen PB1, Godtfredsen NS2, Grann O3, Pors B4, Andersen KK5, Larsen HB6, 
Dalsgaard LS6, Søndergaard JD1, Lavesen M7, Sørensen TB8
1Pﬁzer Denmark ApS., Ballerup, Denmark, 2Bispebjerg Hospital, Copenhagen, Denmark, 3The 
Municipality of Aalborg, Aalborg, Denmark, 4The Municipality of Horsens, Horsens, Denmark, 
5Technical University of Denmark, Lyngby, Denmark, 6Boehringer Ingelheim, Copenhagen, 
Denmark, 7Hillerød Hospital, Hillerød, Denmark, 8The Regional Hospital Horsens, Brædstrup 
and Odder, Horsens, Denmark
More than 400,000 people in Denmark suffers from chronic obstructive lung disease 
(COPD) with implications for their quality of life (QoL). As a chronic disease reha-
bilitation of COPD is important. Today this is the responsibility of the health care 
centres in the municipalities in cooperation with the general practitioners and hospi-
tals. OBJECTIVES: Investigate the improvement in quality of life for the COPD 
patients entering the health care centres for rehabilitation. METHODS: 22 Danish 
municipality health care centres (20% of Danish municipalities and 50% of current 
rehabilitation centres) participated in the project. Each centre had their own rehabilita-
tion strategy and included COPD patients undergoing rehabilitation in the project. 
QoL was one focus for measurement of the effect of the rehabilitation. The 15D 
instrument was chosen due to its high correlation with typical COPD symptoms, pul-
monary function and test capacity, and studies has found it sensitive in COPD. Besides 
QoL other effect indicators were 6 min. walking distance and shuttle walk, as well as 
demographic data was recorded in a database. Data was measured before and after 
rehabilitation in a longitudinal cohort design to measure change in outcome due to 
rehabilitation. RESULTS: 396 COPD patients completing rehabilitation (40% males, 
mean age of 68 years, BMI 25.8, 29% current smokers, 65% ex-smokers, and 40 
pack years of smoking) were included. Comparing pre- and post-rehabilitation the 
QALY value measured with the 15D instrument increased from 0.8 to 0.84 (p  0.01) 
having rehabilitation. This was also regarded as a clinical signiﬁcant change (0.03). 
Comparable with the improvement in quality of life both 6 min. walk and shuttle 
walk improved for the average patient comparing pre- and post-rehabilitation. CON-
CLUSIONS: The study shows that rehabilitation activities of COPD patients in the 
health care centres in Danish municipalities is important as it signiﬁcantly improves 
patients quality of life.
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OBJECTIVES: The aim of this study was to analyse the association between tobacco            
consumption and Health-Related Quality of Life (HRQoL) in a general population 
on the basis of a representative panel dataset in Germany. METHODS: The analysis  
was designed as a cross-sectional study using the data of the “German Socio-Economic 
Panel Study” (SOEP) for the year 2006. The HRQoL was measured by the SF-12v2 
(SOEP-Version with norm-based scores for all dimensions). For each of the eight 
subscores and both composite scores a separate multivariate linear regression analysis 
